Citations

Mayo Clinic

Clear

2500 citation(s) found for "Ma, C Benjamin".

Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research
Toll, Benjamin A. , Moinpour, Carol M. , Gritz, Ellen R., Prindiville, Sheila A. , Sarna, Linda, Leischow, Scott J. , Dresler, Carolyn M., Warren, Graham , Land, Stephanie R , Mitchell, Sandra A , Ostroff, Jamie S , Hatsukami, Dorothy K. , Duffy, Sonia A. , Rigotti, Nancy A. , Brandon, Thomas Henry , Schnoll, Robert A. , Herbst, Roy S. , Cinciripini, Paul M , Fiore, Michael C.

Clinical Cancer Research | February 17, 2016 | Volume: 22 | Issue: 8 | Pages: 1907-1913

10.1158/1078-0432.ccr-16-0104 | PMID 26888828 Get It

Abstract There is strong evidence that cigarette smoking causes adverse outcomes in people with cancer. However, more research is needed regarding those effects and the effects of alternative tobacco products and of secondhand smoke, the effects of cessation (before diagnosis, during treatment, or during survivorship), the biologic mechanisms, and optimal strategies for tobacco dependence treatment in oncology. Fundamentally, tobacco is an important source of variation in clinical treatment trials. Nevertheless, tobacco use assessment has not been uniform in clinical trials. Progress has been impeded by a lack of consensus regarding tobacco use assessment suitable for cancer patients. The NCI-AACR Cancer Patient Tobacco Use Assessment Task Force identified priority research areas and developed recommendations for assessment items and timing of assessment in cancer research. A cognitive interview study was conducted with 30 cancer patients at the NIH Clinical Center to evaluate and improve the measurement items. The resulting Cancer Patient Tobacco Use Questionnaire (C-TUQ) includes “Core” items for minimal assessment of tobacco use at initial and follow-up time points, and an “Extension” set. Domains include the following: cigarette and other tobacco use status, intensity, and past use; use relative to cancer diagnosis and treatment; cessation approaches and history; and secondhand smoke exposure. The Task Force recommends that assessment occur at study entry and, at a minimum, at the end of protocol therapy in clinical trials. Broad adoption of the recommended measures and timing protocol, and pursuit of the recommended research priorities, will help us to achieve a clearer understanding of the significance of tobacco use and cessation for cancer patients. Clin Cancer Res; 22(8); 1907–13. ©2016 AACR.
The phenotypic legacy of admixture between modern humans and Neandertals
Simonti, Corinne , Vernot, Benjamin , Bastarache, Lisa , Böttinger, Erwin P. , Chisholm, Rex L. , Crosslin, David R. , Hebbring, Scott J. , Jarvik, Gail P. , Li, Rongling, Pathak, Jyotishman , Ritchie, Marylyn D. , Roden, Dan M. , Tromp, Gerard , Prato, Jeffrey D., Bush, William S. , Akey, Joshua M. , Denny, Joshua C. , Capra, John A. , Carrell, David , Kullo, Iftikhar J. , Roden, Dan M. , Verma, Shefali S. , Denny, Joshua C , Jarvik, Gail P , Bush, William S

Science | February 12, 2016 | Volume: 351 | Issue: 6274 | Pages: 737-741

10.1126/science.aad2149 | PMID 26912863 Get It

The legacy of human-Neandertal interbreeding Non-African humans are estimated to have inherited on average 1.5 to 4% of their genomes from Neandertals. However, how this genetic legacy affects human traits is unknown. Simonti et al. combined genotyping data with electronic health records. Individual Neandertal alleles were correlated with clinically relevant phenotypes in individuals of European descent. These archaic genetic variants were associated with medical conditions affecting the skin, the blood, and the risk of depression. Science , this issue p. 737
Annual Surgeon Volume and Patient Outcomes Following Laparoscopic Totally Extraperitoneal Inguinal Hernia Repairs
AlJamal, Yazan , Gas, Becca L. , Heller, Stephanie F. , Kendrick, Michael L. , Farley, David R. , AlJamal, Yazan N, Zendejas, Benjamin , Ali, Shahzad M, Ali, Shahzad M. , AlJamal, Yazan N

Journal of Laparoendoscopic & Advanced Surgical Techniques | February 11, 2016 | Volume: 26 | Issue: 2 | Pages: 92-98

10.1089/lap.2015.0368 | PMID 26863294 Get It

Abstract Purpose: Data on laparoscopic totally extraperitoneal inguinal hernia repairs (TEP-IHRs) suggest that approximately 250 operations are needed to gain mastery, but the annual volume required to maintain high-quality outcomes is unknown. Materials and Methods: A retrospective review was performed of every patient undergoing a TEP-IHR at the Mayo Clinic (Rochester, MN) from 1995 to 2011. Analysis focused on the annual volume of 21 staff surgeons and their specific patient outcomes broken up into three groups: Group 1 (G1) ( n = 1 surgeon) performed >30 repairs per year; Group 2 (G2) ( n = 3 surgeons), 15–30 repairs; and Group 3 (G3) ( n = 17), <15 repairs. Results: In total, 1601 patients underwent 2410 TEP-IHRs, with no significant patient demographic differences among groups. Greater annual surgeon volume (G1 > G2 > G3) was associated with improved outcomes as shown by the respective rates for intra- (1%, 2.6%, and 5.6%) and postoperative (13%, 27%, and 36%) complications, need for overnight stay (17%, 23%, and 29%), and hernia recurrence (1%, 4%, and 4.3%) (all P < .05). Surgeons with greater annual operative volumes were more likely to operate on patients with bilateral and recurrent hernias. Surgeons performing at least 15 repairs per year (G1 and G2) showed improvements in quality metrics over time. Conclusions: Annual operative volumes of >30 repairs per year are associated with the highest quality outcomes for TEP-IHR. Operative volumes of at least 15 repairs per year are associated with improvements in quality metrics over time. Mentorship and operative assistance of low-volume TEP-IHR surgeons may be useful in improving patient outcomes.
Author response: Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributions
Lassay, Lisa, Orlikowsky, Thorsten , Brümmendorf, Tim H., Werner, Benjamin , Beier, Fabian , Hummel, Sebastian , Balabanov, Stefan , Dingli, David , Traulsen, Arne

No container title available | January 25, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.08687.019 Get It

Penile and Scrotal Swelling: An Underrecognized Presentation of Crohn's Disease
Barrick, Benjamin J., Tollefson, Megha M. , Schoch, Jennifer J. , McEvoy, Marian T., Hand, Jennifer L. , Wieland, Carilyn N. , Davis, Dawn M. R., Davis, Dawn Marie R.

Pediatric Dermatology | January 14, 2016 | Volume: 33 | Issue: 2 | Pages: 172-177

10.1111/pde.12772 | PMID 26764123 Get It

AbstractBackground: Penile and scrotal swelling can occur as an extraintestinal manifestation of Crohn's disease (CD) and is thought to be an uncommon form of metastatic CD (MCD). Because of the rarity of this manifestation, much is unknown concerning the presentation, treatment, and response to therapy in children with genital MCD. Methods: Boys ages 1 to 17 years presenting with genital edema and a confirmed diagnosis or strong suspicion of CD who were evaluated at the Mayo Clinic between 1996 and 2014 were included for review. We sought to characterize the clinical and pathologic features of genital MCD and response to treatment in our cohort of patients. Results: Eight patients with genital MCD were identified from our institution (mean age 11.4 yrs, range 7–16yrs). Seven (88%) patients experienced cutaneous symptoms before a formal diagnosis of CD was made, and two of the seven had no adverse gastrointestinal symptoms at that time. Patients were prescribed an average of 3.4 medications (topical and systemic) for management of their gastrointestinal CD and MCD. Conclusions: Penile and scrotal swelling can occur as an extraintestinal manifestation of CD and is thought to be an uncommon form of MCD. In boys, genital swelling typically precedes intestinal CD. Treatment of the underlying CD with systemic medications was most helpful in this series. An evaluation for CD is necessary in all patients presenting with unexplained genital swelling.
Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death
Thompson, Agnieszka K., Kelley, Benjamin , Murad, M. Hassan , Baum, Christian L. , Kelley, Benjamin F, Prokop, Larry J. , Murad, M Hassan

JAMA Dermatology | January 14, 2016 | Volume: 152 | Issue: 4 | Pages: 419

10.1001/jamadermatol.2015.4994 | PMID 26762219 Get It

Bileaflet Mitral Valve Prolapse and Risk of Ventricular Dysrhythmias and Death
Nordhues, Benjamin D., Siontis, Konstantinos C. , Ackerman, Michael J. , Asirvatham, Samuel J. , Scott, Christopher G. , Nkomo, Vuyisile T. , Noseworthy, Peter A. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | January 10, 2016 | Volume: 27 | Issue: 4 | Pages: 463-468

10.1111/jce.12914 | PMID 26749260 Get It

Dysrhythmias and Death in BiMVPIntroductionBileaflet mitral valve prolapse (BiMVP) is common among survivors of otherwise unexplained sudden cardiac death, but prognostic implications of BiMVP are unknown. This study evaluated whether patients with BiMVP are at higher risk for ventricular dysrhythmias, ICD placement, or death compared to controls with either single‐leaflet mitral valve prolapse (SiMVP) or no mitral valve prolapse (MVP).Methods and ResultsThis retrospective, matched cohort study included 18,786 patients who underwent echocardiography at Mayo Clinic between June 1990 and September 2014. The study included three cohorts: BiMVP, SiMVP, and controls without MVP. We assessed rates of ventricular dysrhythmias, ICD placement, and all‐cause mortality between groups. BiMVP was associated with higher rates of ventricular tachycardia compared to SiMVP and controls (adjusted HR 1.48 [1.14–1.92], P = 0.003 and 1.40 [1.04–1.88], P = 0.026, respectively); however, there were no statistically significant differences in rates of ventricular fibrillation/cardiac arrest or ICD placement between groups. BiMVP was associated with a lower rate of all‐cause mortality compared to SiMVP and controls (adjusted HR 0.86 [0.79–0.94], P = 0.0008, and 0.55 [0.50–0.60], P < 0.0001, respectively).ConclusionAlthough BiMVP is associated with ventricular tachycardia, it is not associated with an increased risk of cardiac arrest/ventricular fibrillation or ICD implantation and is, paradoxically, associated with a better survival compared to SiMVP or matched controls. The findings suggest that, despite its association with ventricular tachycardia, BiMVP in the absence of other risk factors does not seem to portend a poor prognosis at the population level.
Reliability of 3-Dimensional Measures of Single-Leg Cross Drop Landing Across 3 Different Institutions
DiCesare, Christopher A. , Bates, Nathaniel A. , Foss, Kim D. Barber , Thomas, Staci , Wordeman, Samuel C., Sugimoto, Dai , Roewer, Benjamin D., McKeon, Jennifer M. Medina, Stasi, Stephanie Di , Noehren, Brian , Ford, Kevin R. , Kiefer, Adam W. , Hewett, Timothy E. , Myer, Gregory D. , Bates, Nathaniel A

Orthopaedic Journal of Sports Medicine | December 30, 2015 | Volume: 3 | Issue: 12 | Pages: No page available

10.1177/2325967115617905 | PMID 26779550 Get It

Background: Anterior cruciate ligament (ACL) injuries are physically and financially devastating but affect a relatively small percentage of the population. Prospective identification of risk factors for ACL injury necessitates a large sample size; therefore, study of this injury would benefit from a multicenter approach. Purpose: To determine the reliability of kinematic and kinetic measures of a single-leg cross drop task across 3 institutions. Study Design: Controlled laboratory study. Methods: Twenty-five female high school volleyball players participated in this study. Three-dimensional motion data of each participant performing the single-leg cross drop were collected at 3 institutions over a period of 4 weeks. Coefficients of multiple correlation were calculated to assess the reliability of kinematic and kinetic measures during the landing phase of the movement. Results: Between-centers reliability for kinematic waveforms in the frontal and sagittal planes was good, but moderate in the transverse plane. Between-centers reliability for kinetic waveforms was good in the sagittal, frontal, and transverse planes. Conclusion: Based on these findings, the single-leg cross drop task has moderate to good reliability of kinematic and kinetic measures across institutions after implementation of a standardized testing protocol. Clinical Relevance: Multicenter collaborations can increase study numbers and generalize results, which is beneficial for studies of relatively rare phenomena, such as ACL injury. An important step is to determine the reliability of risk assessments across institutions before a multicenter collaboration can be initiated.
N‐Phenylbenzamides as Potent Inhibitors of the Mitochondrial Permeability Transition Pore
Roy, Sudeshna , Šileikytė, Justina , Neuenswander, Benjamin, Hedrick, Michael P., Chung, Thomas D.Y. , Schoenen, Frank J. , Forte, Michael , Bernardi, Paolo , Aubé, Jeffrey

ChemMedChem | December 23, 2015 | Volume: 11 | Issue: 3 | Pages: 283-288

10.1002/cmdc.201500545 | PMID 26693836 Get It

AbstractPersistent opening of the mitochondrial permeability transition pore (PTP), an inner membrane channel, leads to mitochondrial dysfunction and renders the PTP a therapeutic target for a host of life‐threatening diseases. Herein, we report our effort toward identifying small‐molecule inhibitors of this target through structure–activity relationship optimization studies, which led to the identification of several potent analogues around the N‐phenylbenzamide compound series identified by high‐throughput screening. In particular, compound 4 (3‐(benzyloxy)‐5‐chloro‐N‐(4‐(piperidin‐1‐ylmethyl)phenyl)benzamide) displayed noteworthy inhibitory activity in the mitochondrial swelling assay (EC50=280 nm), poor‐to‐very‐good physicochemical as well as in vitro pharmacokinetic properties, and conferred very high calcium retention capacity to mitochondria. From the data, we believe compound 4 in this series represents a promising lead for the development of PTP inhibitors of pharmacological relevance.